McCourt Marion

McCourt Marion (EVP Commercial) sold 1,000 shares of REGN for $1,054,060.00 on 2024-10-01.

McCourt Marion sold 1,000 shares at $1,054.06, reducing holdings by 7.2%, after the stock had declined 13.2% over the prior 30 days and is now 15.6% below its 52-week high of $1,201.76. His cross-ticker track record shows a 50.00% well-timed rate on prior sells, indicating moderate historical precision in exit timing. However, his same-ticker REGN history shows mixed results: only 1 of 2 prior sells were well-timed at the 90-day mark, with his most recent REGN sale on 2024-09-03 down 13.9% at the 30-day check. The transaction occurs in a fundamentally stable company with $3.5B quarterly revenue, 7.8% annual growth, and a P/E of 22.06, providing no signal of distress. The sale appears discretionary and modest relative to his remaining 12.9K share position.

McCourt Marion (EVP Commercial) sold 1,000 shares of REGN at $1,178.73 on 2024-09-03; currently -4.3% from 52-week high.

McCourt Marion sold 1,000 shares at $1,178.73, reducing holdings by 7.2% from 13,931 to 12,931 shares. The sale occurred near the 52-week peak ($1,201.76), with the stock now trading -4.3% below that high. His prior three REGN sales (June, July, August 2024) all saw gains in the following 30 days (+4.5%, +3.1%, +11.7%), and the June sale posted a +20.9% 90-day return, indicating prior REGN sales were not well-timed on a 90-day horizon. Over his cross-ticker history, his 3 prior sells averaged a 90-day return of +20.9% with a 0.00% well-timed rate, meaning they consistently missed subsequent gains. This September sale follows the same monthly pattern and timing window as the prior three REGN transactions, occurring as the stock has rallied +7.9% in 30 days and +14.7% in 90 days.

EVP Commercial Marion McCourt sold 1,137 shares of REGN for $1,206,197.82 on 2024-08-01; stock up 3.6% in 30 days since sale.

Marion McCourt (EVP Commercial) executed an open-market sale of 1,137 shares at $1,060.86, reducing holdings by 8.1% to 12,931 shares. The stock has appreciated 3.6% over 30 days post-transaction and currently trades at $1071.28, suggesting the sale was executed before subsequent gains. Across his prior REGN transactions, McCourt sold on 2024-07-01 and 2024-06-03, both followed by positive 30-day returns (+3.1% and +4.5% respectively). His cross-ticker track record shows 2 prior open-market sells with an average 30-day return of +3.8%, indicating a pattern of selling into strength rather than ahead of declines.

EVP Marion McCourt sells 1,137 REGN shares at $1,047.11; holds 12,931 post-sale.

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, sold 1,137 shares (12.9K shares post-transaction) on 2024-07-01 at $1,047.11 for a total value of $1,190,564.07. This represents an 8.1% reduction in holdings. The stock has since recovered, trading at $1,044.66 with strong recent momentum (30-day change: +6.6%, 90-day change: +9.8%), and remains 2.5% below its 52-week high of $1,071.19. The company's fundamentals appear solid with revenue of $3,145,000,000.00 and net income of $722,000,000.00 in the latest quarter, alongside 7.8% annual revenue growth. The insider's minimal cross-ticker track record (1 prior sell) and limited same-ticker history (prior sale on 2024-06-03 with outcomes not yet measurable) provide insufficient pattern evidence for timing interpretation.